Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:BPTH
- CUSIP: N/A
- Web: www.biopathholdings.com
Capitalization:- Market Cap: $38.82 million
- Outstanding Shares: 100,056,000
Average Prices:- 50 Day Moving Avg: $0.31
- 200 Day Moving Avg: $0.49
- 52 Week Range: $0.25 - $1.50
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.53
- P/E Growth: 0.000
Sales & Book Value:- Annual Revenue: $13,000.00
- Price / Sales: 2,986.29
- Book Value: $0.09 per share
- Price / Book: 4.41
Profitability:- EBIDTA: ($8,690,000.00)
- Return on Equity: -56.53%
- Return on Assets: -43.24%
Debt:- Current Ratio: 13.65%
- Quick Ratio: 13.65%
Misc:- Average Volume: 596,758 shs.
- Beta: 3.04
- Short Ratio: 5.25
Frequently Asked Questions for Bio-Path Holdings (NASDAQ:BPTH)
What is Bio-Path Holdings' stock symbol?
Bio-Path Holdings trades on the NASDAQ under the ticker symbol "BPTH."
How were Bio-Path Holdings' earnings last quarter?
Bio-Path Holdings, Inc. (NASDAQ:BPTH) announced its earnings results on Thursday, August, 10th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.01. View Bio-Path Holdings' Earnings History.
When will Bio-Path Holdings make its next earnings announcement?
Where is Bio-Path Holdings' stock going? Where will Bio-Path Holdings' stock price be in 2017?
2 analysts have issued 12-month price objectives for Bio-Path Holdings' shares. Their forecasts range from $2.00 to $5.00. On average, they expect Bio-Path Holdings' stock price to reach $3.50 in the next twelve months. View Analyst Ratings for Bio-Path Holdings.
Who are some of Bio-Path Holdings' key competitors?
Some companies that are related to Bio-Path Holdings include Brainstorm Cell Therapeutics (BCLI), CytRx Corporation (CYTR), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Navidea Biopharmaceuticals (NAVB), Galectin Therapeutics (GALT), Infinity Pharmaceuticals (INFI), ReNeuron Group Plc (RENE), Fibrocell Science (FCSC), OvaScience (OVAS), Sunesis Pharmaceuticals (SNSS), Abzena PLC (ABZA), Jaguar Animal Health (JAGX), Aptose Biosciences (APTO), Prima BioMed Ltd (PBMD), Cleveland BioLabs (CBLI), AEterna Zentaris (AEZS) and Scancell Holdings Plc (SCLP).
Who are Bio-Path Holdings' key executives?
Bio-Path Holdings' management team includes the folowing people:
- Peter Henry Nielsen, Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer, Treasurer
- Ulrich W. Mueller Ph.D., Chief Operating Officer, Secretary
- Douglas P. Morris, Director
- Heath W. Cleaver CPA, Independent Director
- Mark P. Colonnese, Independent Director
Who owns Bio-Path Holdings stock?
Bio-Path Holdings' stock is owned by a number of of institutional and retail investors. Top institutional investors include University of Texas Investment Managment Co. (4.01%), Vanguard Group Inc. (2.55%), Legal & General Group Plc (1.85%), HighTower Advisors LLC (1.27%) and Northern Trust Corp (0.32%). View Institutional Ownership Trends for Bio-Path Holdings.
Who sold Bio-Path Holdings stock? Who is selling Bio-Path Holdings stock?
Who bought Bio-Path Holdings stock? Who is buying Bio-Path Holdings stock?
How do I buy Bio-Path Holdings stock?
Shares of Bio-Path Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bio-Path Holdings' stock price today?
One share of Bio-Path Holdings stock can currently be purchased for approximately $0.39.
MarketBeat Community Rating for Bio-Path Holdings (NASDAQ BPTH)MarketBeat's community ratings are surveys of what our community members think about Bio-Path Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Bio-Path Holdings (NASDAQ:BPTH) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $3.50 (802.06% upside) |
Analysts' Ratings History for Bio-Path Holdings (NASDAQ:BPTH)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/11/2017 | HC Wainwright | Set Price Target | Buy | $5.00 | High |  |
| 4/5/2017 | Maxim Group | Set Price Target | Buy | $2.00 | High | |
| 8/11/2016 | Rodman & Renshaw | Set Price Target | Buy | $5.00 | N/A | |
(Data available from 9/20/2015 forward)
Earnings History for Bio-Path Holdings (NASDAQ:BPTH)Earnings History by Quarter for Bio-Path Holdings (NASDAQ BPTH)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/8/2017 | | ($0.02) | | | | | N/A | |
| 8/10/2017 | Q2 2017 | ($0.02) | ($0.03) | | | View | Listen | |
| 5/11/2017 | Q1 2017 | ($0.02) | ($0.01) | | | View | N/A | |
| 3/15/2017 | 12/31/2016 | ($0.03) | ($0.01) | | $0.01 million | View | Listen | |
| 11/9/2016 | Q316 | ($0.02) | ($0.02) | $2.50 million | | View | Listen | |
| 8/9/2016 | Q2 | ($0.02) | ($0.02) | | | View | N/A | |
| 5/11/2016 | Q1 | ($0.01) | ($0.02) | $2.33 million | | View | Listen | |
| 3/16/2016 | Q4 | ($0.01) | ($0.02) | | $1.46 million | View | N/A | |
| 11/10/2015 | Q315 | | ($0.02) | | | View | N/A | |
| 8/11/2015 | Q2 2015 | ($0.03) | ($0.01) | | | View | N/A | |
| 3/17/2015 | Q4 2014 | $0.01 | ($0.02) | | | View | N/A | |
| 11/17/2014 | Q3 2014 | ($0.01) | ($0.01) | | | View | N/A | |
| 8/18/2014 | Q214 | ($0.01) | ($0.01) | | | View | N/A | |
| 4/2/2014 | | $0.01 | $0.01 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Bio-Path Holdings (NASDAQ:BPTH)Current Year EPS Consensus Estimate: $-0.080 EPS
Next Year EPS Consensus Estimate: $-0.110 EPS
Dividend History for Bio-Path Holdings (NASDAQ:BPTH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Bio-Path Holdings (NASDAQ:BPTH)Insider Ownership Percentage: 12.54%
Institutional Ownership Percentage: 15.16%
Insider Trades by Quarter for Bio-Path Holdings (NASDAQ:BPTH)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/13/2015 | Michael J Garrison | Director | Buy | 7,343 | $1.22 | $8,958.46 | |
| 7/9/2015 | Michael J Garrison | Director | Buy | 8,724 | $1.17 | $10,207.08 | |
| 7/8/2015 | Michael J Garrison | Director | Buy | 60,000 | $1.19 | $71,400.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Bio-Path Holdings (NASDAQ:BPTH)
Latest Headlines for Bio-Path Holdings (NASDAQ:BPTH)
| Source: |
|
| Date | Headline |
|---|
 | Bio-Path (BPTH) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 5:52 PM |
 | Bio-Path Holdings to Present at the Rodman & Renshaw Annual Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - September 5 at 11:19 PM |
 | Bio-Path Holdings to Present at the Rodman & Renshaw Annual Healthcare Conference
finance.yahoo.com - September 5 at 6:17 PM |
 | -$0.02 EPS Expected for Bio-Path Holdings, Inc. (BPTH) This Quarter
www.americanbankingnews.com - September 4 at 4:28 AM |
| Bio-Path Holdings, Inc. (BPTH) Downgraded by ValuEngine to Strong Sell
www.americanbankingnews.com - September 3 at 8:26 PM |
| Zacks: Analysts Expect Bio-Path Holdings, Inc. (BPTH) Will Post Earnings of -$0.02 Per Share
www.americanbankingnews.com - August 16 at 4:32 PM |
| Bio-Path Holdings, Inc. (NASDAQ:BPTH) PT Set at $5.00 by HC Wainwright
www.americanbankingnews.com - August 13 at 3:32 PM |
| Bio-Path Holdings, Inc. (NASDAQ:BPTH) Releases Earnings Results
www.americanbankingnews.com - August 11 at 2:34 PM |
| Bio-Path Holdings' (BPTH) CEO Peter Nielsen on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 10 at 5:50 PM |
| Bio-Path reports 2Q loss
finance.yahoo.com - August 10 at 5:50 PM |
| Bio-Path Holdings to Announce Second Quarter 2017 Financial Results on August 10, 2017 - GlobeNewswire (press release)
globenewswire.com - August 4 at 4:58 PM |
| Bio-Path Holdings to Announce Second Quarter 2017 Financial Results on August 10, 2017
finance.yahoo.com - August 3 at 6:08 PM |
| Bio-Path Holdings, Inc. (NASDAQ:BPTH) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:17 AM |
| Bio-Path Holdings Receives Notice of Allowance for Key U.S. Composition of Matter Patent
finance.yahoo.com - July 31 at 4:44 PM |
| Bio-Path Holdings Receives Notice of Allowance for Key US Composition of Matter Patent - GlobeNewswire (press release)
globenewswire.com - July 20 at 11:21 PM |
| Bio-Path Holdings, Inc. (NASDAQ:BPTH) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - July 20 at 8:42 AM |
 | Bio-Path Holdings (BPTH) Granted Allowance for Key US Composition of Matter Patent for DNAbilize by USPTO - StreetInsider.com
www.streetinsider.com - July 19 at 5:52 PM |
 | Bio-Path Holdings Appoints Mark Colonnese to its Board of Directors - Nasdaq
www.nasdaq.com - July 17 at 5:04 PM |
| Bio-Path Holdings Appoints Mark Colonnese to its Board of Directors
finance.yahoo.com - July 17 at 12:23 PM |
| Bio-Path Holdings, Inc. (BPTH) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - July 12 at 7:11 PM |
| Zacks: Brokerages Anticipate Bio-Path Holdings, Inc. (BPTH) Will Announce Earnings of -$0.02 Per Share
www.americanbankingnews.com - July 5 at 7:45 AM |
 | Stonegate Capital Partners Initiates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) - Baystreet.ca
www.baystreet.ca - June 30 at 4:49 PM |
| Stonegate Capital Partners Initiates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH)
finance.yahoo.com - June 29 at 5:51 PM |
| Brokerages Expect Bio-Path Holdings Inc (BPTH) Will Announce Earnings of -$0.02 Per Share
www.americanbankingnews.com - June 9 at 7:40 AM |
| Reviewing Adamis Pharmaceuticals Corp (ADMP) & Bio-Path Holdings (BPTH)
www.americanbankingnews.com - June 3 at 10:40 PM |
| Zacks: Brokerages Anticipate Bio-Path Holdings Inc (BPTH) Will Announce Earnings of -$0.02 Per Share
www.americanbankingnews.com - May 13 at 12:02 AM |
| Bio-Path Holdings Inc (BPTH) Posts Quarterly Earnings Results
www.americanbankingnews.com - May 12 at 11:48 AM |
| Bio-Path Holdings' (BPTH) CEO Peter Nielsen on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 4:36 PM |
| Bio-Path Holdings Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 11 at 4:36 PM |
| Bio-Path reports 1Q loss
finance.yahoo.com - May 11 at 4:36 PM |
| Bio-Path Holdings Inc (BPTH) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - May 7 at 7:16 AM |
| Bio-Path Holdings to Announce First Quarter 2017 Financial Results on May 11, 2017
finance.yahoo.com - May 4 at 4:07 PM |
| Positive Media Coverage Likely to Affect Bio-Path Holdings (BPTH) Stock Price
www.americanbankingnews.com - May 4 at 12:36 AM |
| Bio-Path Holdings (BPTH) Earns Daily Media Sentiment Score of 0.13
www.americanbankingnews.com - April 27 at 8:08 PM |
| Bio-Path Holdings (BPTH) Receives Daily Coverage Optimism Rating of 0.57
www.americanbankingnews.com - April 21 at 8:47 AM |
| Bio-Path Holdings (BPTH) Looks Good: Stock Moves 13% Higher - Yahoo Finance
finance.yahoo.com - April 19 at 1:11 PM |
| Bio-Path Holdings Inc (BPTH) Short Interest Up 2.3% in March
www.americanbankingnews.com - April 19 at 7:14 AM |
| Bio-Path Holdings (BPTH) Getting Very Favorable Media Coverage, Analysis Shows
www.americanbankingnews.com - April 18 at 8:56 AM |
| Bio-Path Holdings Announces Appointment of Dr. William Hahne as Vice President of Clinical Development
finance.yahoo.com - April 17 at 12:25 PM |
| Somewhat Favorable News Coverage Extremely Likely to Impact Bio-Path Holdings (BPTH) Stock Price
www.americanbankingnews.com - April 15 at 10:29 AM |
| Bio-Path Holdings Inc (BPTH) Given a $5.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 7 at 10:44 PM |
| Bio-Path Holdings Presents Results Showing Potential of BP1002 as Treatment for Aggressive Non-Hodgkin’s Lymphoma
finance.yahoo.com - April 7 at 8:40 AM |
| Bio-Path Holdings Inc (BPTH) Given a $2.00 Price Target at Maxim Group
www.americanbankingnews.com - April 5 at 6:45 PM |
| Bio-Path Holdings (BPTH) Presents At Oppenheimer 27th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 23 at 1:49 AM |
| HC Wainwright Reiterates $5.00 Price Target for Bio-Path Holdings Inc (BPTH)
www.americanbankingnews.com - March 22 at 9:11 AM |
| Zacks Investment Research Upgrades Bio-Path Holdings Inc (BPTH) to "Buy"
www.americanbankingnews.com - March 20 at 9:49 PM |
| Bio-Path Holdings Inc (BPTH) Announces Quarterly Earnings Results
www.americanbankingnews.com - March 16 at 10:43 AM |
| Bio Path Holdings Inc Earnings Call scheduled for 8:30 am ET today
biz.yahoo.com - March 15 at 9:21 PM |
 | Bio-Path Holdings Reports Full Year 2016 Financial Results
us.rd.yahoo.com - March 15 at 4:20 PM |
| BIO-PATH HOLDINGS INC Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 15 at 4:20 PM |
Bio-Path Holdings (BPTH) Chart for Wednesday, September, 20, 2017
